Calliditas Therapeutics Presents Additional Data Analyses From Phase 3 NeflgArd Trial Of Nefecon In Primary IgA Nephropathy At ISN World Congress Of Nephrology 2024
Calliditas Therapeutics Presents Additional Data Analyses From Phase 3 NeflgArd Trial Of Nefecon In Primary IgA Nephropathy At ISN World Congress Of Nephrology 2024
Calliditas Therapeutics在2024年ISN世界腎臟病大會上公佈了Nefecon治療原發性IgA腎病的3期NefelGard試驗的更多數據分析
Richard Philipson, Chief Medical Officer of Calliditas, said, "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient's racial and ethnic backgrounds."
Calliditas首席醫學官理查德·菲利普森說：“這些額外的數據進一步強化了Nefecon對整個研究人群的影響，無論基線UPCR水平或患者的種族和族裔背景如何。”
資訊熱榜
更新時間